Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2alpha antagonists
申请人:——
公开号:US20020128233A1
公开(公告)日:2002-09-12
The present invention provides novel compounds represented by the general
1
wherein m, n, X, Y, Z, R, R
1
and R
2
are as defined in the specification or a pharmaceutically acceptable salt thereof. The novel compounds are PGF
2&agr;
antagonists, useful in pharmaceutical compositions for treating PGF
2&agr;
-mediated disease responses such as inflammatory reactions relating to rheumatoid arthritis and psoriasis, reproductive disorders, bronchoconstrictive disorders (asthma), excessive bone breakdown (osteoporosis), peptic ulcers, heart disease, platelet aggregation and thrombosis.
本发明提供了由通式1表示的新化合物,其中m,n,X,Y,Z,R,R1和R2如规范中定义或其药学上可接受的盐。这些新化合物是PGF2α拮抗剂,可用于制备药物组合物,用于治疗PGF2α介导的疾病反应,如与类风湿性关节炎和牛皮癣有关的炎症反应,生殖障碍,支气管收缩性疾病(哮喘),过度骨质破坏(骨质疏松症),消化性溃疡,心脏病,血小板聚集和血栓形成。